Smoldering and polarized inflammation in the initiation and promotion of malignant disease

Cancer Cell

Volumn 7, Issue 3, 2005, Pages 211-217

  Balkwill, Frances ^a,b   Charles, Kellie A ^a   Mantovani, Alberto ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CELECOXIB; CHEMOKINE RECEPTOR ANTAGONIST; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE RECEPTOR ANTAGONIST; EXEMESTANE; I KAPPA B; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6 ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEASOME INHIBITOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ZOLEDRONIC ACID;

BARRETT ESOPHAGUS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SUSCEPTIBILITY; CHRONIC INFLAMMATION; CLINICAL TRIAL; COLON CARCINOGENESIS; COLORECTAL CANCER; DNA POLYMORPHISM; DRUG CLEARANCE; GENE MUTATION; HUMAN; INNATE IMMUNITY; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MYCOBACTERIUM TUBERCULOSIS; MYELOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PLASTICITY; POLARIZATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 17644394616     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2005.02.013     Document Type: Short Survey

References (83)

1. M.J. Anasagasti, E. Olaso, F. Calvo, L. Mendoza, J.J. Martin, J. Bidaurrazaga, and F. Vidal-Vanaclocha Interleukin 1-dependent and -independent mouse melanoma metastases J. Natl. Cancer Inst. 89 1997 645 651
2. R.N. Apte, and E. Voronov Interleukin-1-a major pleiotropic cytokine in tumor-host interactions Semin. Cancer Biol. 12 2002 277 290
3. C.H. Arnott, K.A. Scott, R.J. Moore, A. Hewer, D.H. Phillips, P. Parker, F.R. Balkwill, and D.M. Owens Tumour necrosis factor-α mediates tumour promotion via a PKCα-AP-1-dependent pathway Oncogene 21 2002 4728 4738
4. C.H. Arnott, K.A. Scott, R.J. Moore, S.C. Robinson, R.G. Thompson, and F.R. Balkwill Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development Oncogene 23 2004 1902 1910
5. E. Assenat, S. Gerbal-Chaloin, D. Larrey, J. Saric, J.M. Fabre, P. Maurel, M.J. Vilarem, and J.M. Pascussi Interleukin 1β inhibits CAR-induced expression of hepatic genes involved in drug and bilurubin clearance Hepatology 40 2004 951 960
6. F. Balkwill Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 13 2002 135 141
7. F.R. Balkwill Cancer and the chemokine network Nat. Rev. Cancer 2004 000 000 in press
8. F. Balkwill, and A. Mantovani Inflammation and cancer: Back to Virchow Lancet 357 2001 539 545
9. R. Bataille, B. Barlogie, Z.Y. Lu, J.F. Rossi, T. Lavabre-Bertrand, T. Beck, J. Wijdenes, J. Brochier, and B. Klein Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma Blood 86 1995 685 691
10. C. Becker, M.C. Fantini, C. Schramm, H.A. Lehr, S. Wirtz, A. Nikolaev, J. Burg, S. Strand, R. Kiesslich, and S. Huber TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling Immunity 21 2004 491 501
11. L. Bingle, N.J. Brown, and C.E. Lewis The role of tumour associated macrophages in tumour progression: Implications for new anticancer therapies J. Pathol. 196 2002 254 265
12. E. Bromwich, D.C. McMillan, G.W. Lamb, P.A. Vasey, and M. Aitchison The systemic inflammatory response, performance status and survival in patients undergoing α-interferon treatment for advanced renal cancer Br. J. Cancer 91 2004 1236 1238
13. V. Bronte, P. Serafini, A. Mazzoni, D.M. Segal, and P. Zanovello L-arginine metabolism in myeloid cells controls T-lymphocyte functions Trends Immunol. 24 2003 302 306
14. J.R. Cerhan, K.E. Anderson, C.A. Janney, C.M. Vachon, T.E. Witzig, and T.M. Habermann Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma Int. J. Cancer 106 2003 784 788
15. E.T. Chang, T. Zheng, E.G. Weir, M. Borowitz, R.B. Mann, D. Spiegelman, and N.E. Mueller Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study J. Natl. Cancer Inst. 96 2004 305 315
16. F. Chen Endogenous inhibitors of nuclear factor-κB, an opportunity for cancer control Cancer Res. 64 2004 8135 8138
17. L.W. Chow, J.L. Wong, and M. Toi Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: Preliminary report J. Steroid Biochem. Mol. Biol. 86 2003 443 447
18. H. Choy, and L. Milas Enhancing radiotheraphy with cyclooxygenase-2 enzyme inhibitors: A rational advance? J. Natl. Cancer Inst. 95 2003 1440 1452
19. P.C. Chulada, M.B. Thompson, J.F. Mahler, C.M. Doyle, B.W. Gaul, C. Lee, H.F. Tiano, S.G. Morham, O. Smithies, and R. Langenbach Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice Cancer Res. 60 2000 4705 4708
20. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 2002 860 867
21. L.M. Coussens, W.W. Raymond, G. Bergers, M. Laig-Webseter, O. Behrendtsen, Z. Werb, G.H. Caughey, and D. Hanahan Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis Genes Dev. 13 1999 1382 1397
22. T.J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J.R. Conejo-Garcia, L. Zhang, and M. Burow Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat. Med. 10 2004 942 949
23. C. Cursiefen, L. Chen, L.P. Borges, D. Jackson, J. Cao, C. Radziejewski, P.A. D'Amore, M.R. Dana, S.J. Wiegand, and J.W. Streilein VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment J. Clin. Invest. 113 2004 1040 1050
24. G.P. Dunn, L.J. Old, and R.D. Schreiber The immunobiology of cancer immunosurveillance and immunoediting Immunity 21 2004 137 148
25. E.M. El-Omar, M. Carrington, W.-H. Chow, K.E.L. McColl, J.H. Bream, H.A. Young, J. Herrera, J. Lissowska, C.-C. Yiun, and N. Rothman Interleukin-1 polymorphisms associated with increased risk of gastric cancer Nature 404 2000 398 402
26. W.B. Ershler, and E.T. Keller Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty Annu. Rev. Med. 51 2000 245 270
27. M. Feldmann Development of anti-TNF therapy for rheumatoid arthritis Nat. Rev. Immunol. 2 2002 364 371
28. T. Furuta, E.M. El-Omar, F. Xiao, N. Shirai, M. Takashima, H. Sugimura, and H. Sugimurra Interleukin 1β polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan Gastroenterology 123 2002 92 105
29. S. Galban, J. Fan, J.L. Martindale, C. Cheadle, B. Hoffman, M.P. Woods, G. Temeles, J. Brieger, J. Decker, and M. Gorospe von Hippel-Lindau protein-mediated repression of tumor necrosis factor α translation revealed through use of cDNA arrays Mol. Cell. Biol. 23 2003 2316 2328
30. K. Garber Aspirin for cancer chemoprevention: Still a headache? J. Natl. Cancer Inst. 96 2004 252 253
31. G. Gasparini, R. Longo, R. Sarmiento, and A. Morabito Inhibitors of cyclo-oxygenase 2: A new class of anticancer agents? Lancet Oncol. 4 2003 605 615
32. M. Giraudo, M. Inoue, and D. Hanahan An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis J. Clin. Invest. 114 2004 623 633
33. S. Gordon Alternative activation of macrophages Nat. Rev. Immunol. 3 2003 23 35
34. F.R. Greten, L. Eckman, T.F. Greten, J.M. Park, Z.-W. Li, L.J. Egan, and M.F. Kagnoff IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer Cell 118 2004 285 296
35. T.B. Harris, L. Ferrucci, R.P. Tracy, M.C. Corti, S. Wacholder, W.H. Ettinger Jr., H. Heimovitz, H.J. Cohen, and R. Wallace Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly Am. J. Med. 106 1999 506 512
36. D. Honemann, M. Chatterjee, R. Savino, K. Bommert, R. Burger, M. Gramatzki, B. Dorken, and R.C. Bargou The IL-6 receptor antagonist Sant-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells Int. J. Cancer 93 2001 674 680
37. S. Hori, T. Nomura, and S. Sakaguchi Control of regulatory T cell development by the transcription factor Foxp3 Science 14 2003 1057 1061
38. J. Houghton, C. Stoicov, S. Nomura, A.B. Rogers, J. Carlson, H. Li, X. Cai, J.G. Fox, J.R. Goldenring, and T.C. Wang Gastric cancer originating from bone marrow-derived calls Science 306 2004 1568 1571
39. S.P. Hussain, L.J. Hofseth, and C.C. Harris Radical causes of cancer Nat. Rev. Cancer 3 2003 276 285
40. R.F. Jacoby, K. Seibert, C.E. Cole, G. Kelloff, and R.A. Lubet The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis Cancer Res. 60 2000 5040 5044
41. M. Jaiswal, N.F. LaRusso, L.J. Burgart, and G.J. Gores Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism Cancer Res. 60 2000 184 190
42. M. Jaiswal, N.F. LaRusso, and G.J. Gores Nitric oxide in gastrointestinal epithelial cell carcinogenesis: Linking inflammation to oncogenesis Am. J. Physiol. Gastrointest. Liver Physiol. 281 2001 G626 G634
43. J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, W.D. Schwieterman, J.N. Siegel, and M.M. Braun Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent N. Engl. J. Med. 345 2001 1098 1104
44. J.K. Kiecolt-Glaser, K.J. Preacher, R.C. MacCallum, C. Atkinson, W.B. Malarkey, and R. Glaser Chronic stress and age-related increases in the proinflammatory cytokine IL-6 Proc. Natl. Acad. Sci. USA 100 2003 9090 9095
45. H. Kitakata, Y. Nemoto-Sasaki, Y. Takahashi, T. Kondo, M. Mai, and N. Mukaida Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells Cancer Res. 62 2002 6682 6687
46. T. Kitamura, M. Itoh, T. Noda, M. Matsuura, and K. Wakabayashi Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice Int. J. Cancer 109 2004 576 580
47. K.T. Kivisto, H.K. Kroemer, and M. Eichelbaum The role of human cytochrome P450 enzymes in the metabolism of anticancer agents - implications for drug interactions Br. J. Clin. Pharmacol. 40 1995 523 530
48. B. Knight, G.C.T. Yeoh, K.L. Husk, T. Ly, L.J. Abraham, C. Yu, J.A. Rhim, and N. Fausto Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice J. Exp. Med. 192 2000 1809 1818
49. C.-H. Koehne, and R.N. Dubois COX-2 inhibition and colorectal cancer Semin. Oncol. 31 2004 12 21
50. H. Korner, E. Cretney, P. Wilhelm, J.M. Kelly, M. Rollinghoff, J.D. Sedgwick, and M.J. Smyth Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype J. Exp. Med. 191 2000 89 96
51. E.Y. Lin, A.V. Nguyen, R.G. Russell, and J.W. Pollard Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy J. Exp. Med. 193 2001 727 739
52. F.A. Mahmoud, and N.I. Rivera The role of C-reactive protein as a prognostic indicator in advanced cancer Curr. Oncol. Rep. 4 2002 250 255
53. A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes Trends Immunol. 23 2002 549 555
54. A. Mantovani, P. Allavena, and A. Sica Tumour-associated macrophages as a prototypic type II polarised phagocyte population: Role in tumour progression Eur. J. Cancer 40 2004 1660 1667
55. A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi, and M. Locati The chemokine system in diverse forms of macrophage activation and polarization Trends Immunol. 25 2004 677 686
56. R. Moore, D. Owens, G. Stamp, N. East, H. Holdworth, C. Arnott, F. Burke, M. Pasparakis, G. Kollias, and F. Balkwill Tumour necrosis factor-α deficient mice are resistant to skin carcinogenesis Nat. Med. 5 1999 828 831
57. E.T. Morgan, T. Li-Masters, and P.Y. Cheng Mechanisms of cytochrome P450 regulation by inflammatory mediators Toxicology 27 2002 207 210
58. T. Nakayama, L. Yao, and G. Tosato Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors J. Clin. Invest. 114 2004 1317 1325
59. R.B. Ness, and C. Cottreau Possible role of ovarian epithelial inflammation in ovarian cancer J. Natl. Cancer Inst. 91 1999 1459 1467
60. E. Obermueller, S. Vosseler, N.E. Fusenig, and M.M. Mueller Cooperative autocrine and paracrine functions of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the progression of skin carcinoma cells Cancer Res. 64 2004 7801 7812
61. H. Ohshima, M. Tatemichi, and T. Sawa Chemical basis of inflammation-induced carcinogenesis Arch. Biochem. Biophys. 1 2003 3 11
62. J.M. Pascussi, S. Gerbal-Chaloin, L. Pichard-Garcia, M. Daujat, J.M. Fabre, P. Maurel, and M.J. Vilarem Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes Biochem. Biophys. Res. Commun. 274 2000 707 713
63. G.D. Peluffo, I. Stillitani, V.A. Rodriguez, M.J. Diament, and S.M. Klein Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs Int. J. Cancer 110 2004 825 830
64. N.D. Perkins NF-κB: Tumor promoter or suppressor? Trends Cell Biol. 14 2004 64 69
65. E. Pikarsky, R.M. Porat, I. Stein, R. Abramovitch, S. Amit, S. Kasem, E. Gutkovich-Pyest, S. Uriell-Shoval, E. Galun, and Y. Ben-Neriah NF-κB functions as a tumour promoter in inflammation-associated cancer Nature 431 2004 4461 4466
66. J.W. Pollard Tumour-educated macrophages promote tumour progression and metastasis Nat. Rev. Cancer 4 2004 71 78
67. L.P. Rivory, K.A. Slaviero, and S.J. Clarke Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response Br. J. Cancer 87 2002 277 280
68. S.C. Robinson, K.A. Scott, J. Wilson, R.G. Thompson, A.E.L. Proudfoot, and F. Balkwill A chemokine receptor antagonist inhibits experimental breast tumor growth Cancer Res. 63 2003 8360 8365
69. E.S. Schernhammer, J.H. Kang, A.T. Chan, D.S. Michaud, H.G. Skinner, E. Giovannucci, G.A. Colditz, and C.S. Fuchs A prospective study of aspirin use and the risk of pancreatic cancer in women J. Natl. Cancer Inst. 96 2004 22 28
70. T. Schioppa, B. Uranchimeg, A. Saccani, S.K. Biswas, A. Doni, A. Rapisarda, S. Bernasconia, S. Saccani, M. Nebuloni, and L. Vago Regulation of the chemokine receptor CXCR4 by hypoxia J. Exp. Med. 198 2003 1391 1402
71. C.S. Seitz, Q. Lin, H. Deng, and P.A. Khavari Alterations in NF-κB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-κB Proc. Natl. Acad. Sci. USA 95 1998 2307 2312
72. K.A. Slaviero, S.J. Clarke, and L.P. Rivory Inflammatory response: An unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy Lancet Oncol. 4 2003 224 232
73. X. Song, E. Voronov, T. Dvorkin, E. Fima, E. Cagnano, D. Benharroch, Y. Shendler, O. Bjorkdahl, S. Segal, C.A. Dinarello, and R.N. Apte Differential effects of IL-1α and IL-1β on tumorigenicity patterns and invasiveness J. Immunol. 171 2003 6448 6456
74. M. Terabe, S. Matsui, J.-M. Park, M. Mamura, N. Noben-Trauth, D.D. Donaldson, W. Chen, S.M. Wahl, S. Ledbetter, and B. Pratt Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: Abrogation prevents tumor recurrence J. Exp. Med. 198 2003 1741 1752
75. M. Trikha, R. Corringham, B. Klein, and J.F. Rossi Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence Clin. Cancer Res. 9 2003 4653 4665
76. H.C. van Zaanen, H.M. Lokhorst, L.A. Aarden, H.J. Rensink, S.O. Warnaar, J. van der Lelie, and M.H. van Oers Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase I dose-escalating study Br. J. Haematol. 102 1998 783 790
77. A.P. Vicari, C. Chiodoni, C. Vaure, S. Ait-Yahia, C. Dercamp, F. Matsos, O. Reynard, C. Taverne, P. Merle, and M.P. Colombo Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody J. Exp. Med. 4 2002 541 549
78. E. Voronov, D.S. Shouval, Y. Krelin, E. Cagnano, D. Benharroch, Y. Iwakura, C.A. Dinarello, and R.N. Apte IL-1 is required for tumor invasiveness and angiogenesis Proc. Natl. Acad. Sci. USA 100 2003 2645 2650
79. W.-H. Wang, J.Q. Huang, G.F. Zheng, S.K. Lam, J. Karlberg, and B.C.-Y. Wong Non-steroidal anti-inflammatory drug use and the risk of gastic cancer: A systematic review and meta-analysis J. Natl. Cancer Inst. 95 2003 1784 1791
80. F. Wolfe, and K. Michaud Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients Arthritis Rheum. 50 2004 1740 1751
81. F. Wolfe, K. Michaud, J. Anderson, and K. Urbansky Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy Arthritis Rheum. 50 2004 372 379
82. E.Y. Woo, H. Yeh, C.S. Chu, K. Schlienger, R.G. Carroll, J.L. Riley, L.R. Kaiser, and C.H. June Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation J. Immunol. 168 2002 4272 4276
83. J. Wyckoff, W. Wang, E.Y. Lin, W. Wang, F. Pixley, E.R. Stanley, T. Graf, J.W. Pollard, J. Segall, and J. Condeelis A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors Cancer Res. 64 2004 7022 7029